DNMT3A and acute myeloid leukemia: This is of potential clinical impact, as it can be a viable therapeutic option, easing the side effect burden of intensive chemotherapy for AML, by potentially substituting cytarabine with olaparib in treating patients with NPM1‐DNMT3A mutated AML.